영아 연축 치료 시장 : 치료 클래스별, 약물 유형별, 조제별, 투여 경로별, 유통 채널별, 최종사용자별, 지역별(2025-2033년)

The global infantile spasms therapeutics market size reached USD 3.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.2 Billion by 2033, exhibiting a growth rate (CAGR) of 3.52% during 2025-2033. The rising prevalence of seizures in infants, increasing health consciousness among the masses resulting in early diagnosis, and the growing number of product approvals and presence of strong pipelines drugs represent some of the key factors driving the market.

Infantile spasms therapeutics refer to the treatment procedures used for treating seizures or an epilepsy syndrome in young children, usually aged between four months and a year of age. An episode of spasm is characterized by the body stiffening suddenly, arms, legs, and head bending forward, the back arching, and short, subtle seizures. Infantile spasm can be caused by brain tumors, birth injuries, infection of the brain, and genetic changes. There are a number of therapeutic options that are available for infantile spams, including steroids, hormone therapy with corticotropin injection gel and glucocorticoids, as well as antiseizure medications. Infantile spasms therapeutics are more likely to provide sustained results if they are implemented within three weeks after the spasms occur, and treatment can be done by monotherapy or combination therapy. Infantile spasms are diagnosed by physical examination, neurological examination, MRI of the brain, and blood and urine examinations.

Infantile Spasms Therapeutics Market Trends:

The increasing prevalence of infantile spasms among newborn babies is a significant factor driving the growth of the market. This can be attributed to a considerable rise in the birth rates across the globe. In line with this, the growing number of product approvals and presence of strong pipelines drugs are impacting the market positively. Continual technological advancements in the treatment of infantile spasms, such as the introduction of seizure alert device for detecting seizures and alerting the caregivers, are providing an impetus to the market. Also, the widespread awareness regarding early diagnosis and treatment is enhancing the penetration rate of infantile spasm drugs, thereby fueling the market growth. However, various factors, such as lesser treatment success rates, high cost of treatment, strict regulations for drug approval, and the augmenting undiagnosed patient pool, are impeding the growth of the infantile spasms therapeutics market. On the contrary, favorable initiatives and programs conducted by the government and private organizations of several countries for promoting awareness regarding the medical condition is creating a positive market outlook. The market is further driven by the extensive research and development (R&D) activities conducted by the key market players focusing on the development of innovative drugs with higher success rates. Some of the other factors contributing to the market include the expanding healthcare expenditure, rising number of collaborations, partnerships and merger and acquisitions (M&As), rapid urbanization, and inflating disposable income levels.

Key Market Segmentation:

Therapeutic Class Insights:

• Anticonvulsants
• Corticosteroids
• Others

Drug Type Insights:

• Vigabatrin
• Adrenocorticotropic Hormone
• Others (Phase III)

Dosage Insights:

• Solid
• Liquid

Route of Administration Insights:

• Oral
• Parenteral
• Others

Distribution Channel Insights:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

End User Insights:

• Hospitals
• Clinics
• Others

Regional Insights:

• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa
• The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for infantile spasms therapeutics. Some of the factors driving the North America infantile spasms therapeutics market include the presence of several key players, inflating disposable income levels, and the widespread awareness regarding early disease diagnosis and prevention.

Competitive Landscape:

• The report has also provided a comprehensive analysis of the competitive landscape in the global infantile spasms therapeutics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include H. Lundbeck A/S, Mallinckrodt plc, ORPHELIA Pharma, Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

• 1. How big is the global infantile spasms therapeutics market?
• 2. What is the expected growth rate of the global infantile spasms therapeutics market during 2025-2033?
• 3. What are the key factors driving the global infantile spasms therapeutics market?
• 4. What has been the impact of COVID-19 on the global infantile spasms therapeutics market?
• 5. What is the breakup of the global infantile spasms therapeutics market based on the therapeutic class?
• 6. What is the breakup of the global infantile spasms therapeutics market based on the drug type?
• 7. What is the breakup of the global infantile spasms therapeutics market based on the dosage?
• 8. What is the breakup of the global infantile spasms therapeutics market based on route of administration?
• 9. What is the breakup of the global infantile spasms therapeutics market based on the distribution channel?
• 10. What is the breakup of the global infantile spasms therapeutics market based on the end user?
• 11. What are the key regions in the global infantile spasms therapeutics market?
• 12. Who are the key players/companies in the global infantile spasms therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Infantile Spasms Therapeutics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Therapeutic Class

• 6.1 Anticonvulsants
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Corticosteroids
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Others
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Drug Type

• 7.1 Vigabatrin
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Adrenocorticotropic Hormone
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Others (Phase III)
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast

8 Market Breakup by Dosage

• 8.1 Solid
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Liquid
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

• 9.1 Oral
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Parenteral
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Others
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Distribution Channel

• 10.1 Hospital Pharmacy
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Retail Pharmacy
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Online Pharmacy
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast

11 Market Breakup by End User

• 11.1 Hospitals
  • 11.1.1 Market Trends
  • 11.1.2 Market Forecast
• 11.2 Clinics
  • 11.2.1 Market Trends
  • 11.2.2 Market Forecast
• 11.3 Others
  • 11.3.1 Market Trends
  • 11.3.2 Market Forecast

12 Market Breakup by Region

• 12.1 North America
  • 12.1.1 United States
    • 12.1.1.1 Market Trends
    • 12.1.1.2 Market Forecast
  • 12.1.2 Canada
    • 12.1.2.1 Market Trends
    • 12.1.2.2 Market Forecast
• 12.2 Asia-Pacific
  • 12.2.1 China
    • 12.2.1.1 Market Trends
    • 12.2.1.2 Market Forecast
  • 12.2.2 Japan
    • 12.2.2.1 Market Trends
    • 12.2.2.2 Market Forecast
  • 12.2.3 India
    • 12.2.3.1 Market Trends
    • 12.2.3.2 Market Forecast
  • 12.2.4 South Korea
    • 12.2.4.1 Market Trends
    • 12.2.4.2 Market Forecast
  • 12.2.5 Australia
    • 12.2.5.1 Market Trends
    • 12.2.5.2 Market Forecast
  • 12.2.6 Indonesia
    • 12.2.6.1 Market Trends
    • 12.2.6.2 Market Forecast
  • 12.2.7 Others
    • 12.2.7.1 Market Trends
    • 12.2.7.2 Market Forecast
• 12.3 Europe
  • 12.3.1 Germany
    • 12.3.1.1 Market Trends
    • 12.3.1.2 Market Forecast
  • 12.3.2 France
    • 12.3.2.1 Market Trends
    • 12.3.2.2 Market Forecast
  • 12.3.3 United Kingdom
    • 12.3.3.1 Market Trends
    • 12.3.3.2 Market Forecast
  • 12.3.4 Italy
    • 12.3.4.1 Market Trends
    • 12.3.4.2 Market Forecast
  • 12.3.5 Spain
    • 12.3.5.1 Market Trends
    • 12.3.5.2 Market Forecast
  • 12.3.6 Russia
    • 12.3.6.1 Market Trends
    • 12.3.6.2 Market Forecast
  • 12.3.7 Others
    • 12.3.7.1 Market Trends
    • 12.3.7.2 Market Forecast
• 12.4 Latin America
  • 12.4.1 Brazil
    • 12.4.1.1 Market Trends
    • 12.4.1.2 Market Forecast
  • 12.4.2 Mexico
    • 12.4.2.1 Market Trends
    • 12.4.2.2 Market Forecast
  • 12.4.3 Others
    • 12.4.3.1 Market Trends
    • 12.4.3.2 Market Forecast
• 12.5 Middle East and Africa
  • 12.5.1 Market Trends
  • 12.5.2 Market Breakup by Country
  • 12.5.3 Market Forecast

13 Drivers, Restraints, and Opportunities

• 13.1 Overview
• 13.2 Drivers
• 13.3 Restraints
• 13.4 Opportunities

14 Value Chain Analysis

15 Porters Five Forces Analysis

• 15.1 Overview
• 15.2 Bargaining Power of Buyers
• 15.3 Bargaining Power of Suppliers
• 15.4 Degree of Competition
• 15.5 Threat of New Entrants
• 15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

• 17.1 Market Structure
• 17.2 Key Players
• 17.3 Profiles of Key Players
  • 17.3.1 H. Lundbeck A/S
    • 17.3.1.1 Company Overview
    • 17.3.1.2 Product Portfolio
    • 17.3.1.3 Financials
    • 17.3.1.4 SWOT Analysis
  • 17.3.2 Mallinckrodt plc
    • 17.3.2.1 Company Overview
    • 17.3.2.2 Product Portfolio
    • 17.3.2.3 Financials
  • 17.3.3 ORPHELIA Pharma
    • 17.3.3.1 Company Overview
    • 17.3.3.2 Product Portfolio
  • 17.3.4 Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.)
    • 17.3.4.1 Company Overview
    • 17.3.4.2 Product Portfolio

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.